Emergent BioSolutions Inc.
EBS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367644
In the last 90 days, Emergent BioSolutions Inc. insiders filed 0 open-market purchases and 2 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $373.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $297.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $145.8K in total
- 2
- 13F holdersQ2 2026, +6 vs. previous quarter
- 194
- 13F valueReported value at the end of Q2 2026
- $373.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $742.9M
- −28.8% year over year
- Net income, FY2025
- $52.6M
- No comparable prior period
- Free cash flow, FY2025
- $156.8M
- +338.0% year over year
- Revenue, Q3 FY2026
- $110.0M
- −52.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.1M
- Shares sold short
- Change
- +395.7K
- +4.1% vs. previous
- Days to cover
- 10.07
- At average daily volume
Superinvestors holding EBS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding EBS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Emergent BioSolutions Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 2026 (view filing)3:45 PM ET | Oct 7 | Same day | DeGolyer Donald WDirector | SSale | −17.8K | $7.09 | −$126.2K | −13.7%111.9K after | 10b5-1 |
| Oct 5, 2026 (view filing)9:16 AM ET | Oct 1 | 4 days | Williams Paul AnthonySVP, Products Business | SSale | −3.00K | $6.53 | −$19.6K | −1.9%156.1K after | 10b5-1 |
| Jul 2, 2026 (view filing)12:57 PM ET | Jul 1 | 1 day | Williams Paul AnthonySVP, Products Business | SSale | −3.00K | $8.40 | −$25.2K | −1.9%159.1K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Zoon Kathryn CDirector | SSale | −17.2K | $8.40 | −$144.5K | −17.7%79.9K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | DeGolyer Donald WDirector | SSale | −15.5K | $8.40 | −$130.0K | −10.7%129.7K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Dayal Sujata TyagiDirector | SSale | −13.8K | $8.40 | −$115.6K | −12.0%100.6K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | Apr 30 | 4 days | Katkin KeithDirector | SSale | −15.5K | $8.28 | −$128.2K | −13.9%96.3K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Williams Paul AnthonySVP, Products Business | SSale | −4.00K | $8.44 | −$33.8K | −6.0%62.7K after | 10b5-1 |
| Dec 9, 2025 (view filing) | Dec 5 | 4 days | Richard RonaldDirector | SSale | −22.0K | $11.97 | −$263.1K | −18.3%98.4K after | 2 lots |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | DeGolyer Donald WDirector | SSale | −17.8K | $10.54 | −$187.6K | −12.9%119.9K after |
Top 10 13F holders, Q2 2026
See all 194 holdersThe largest institutional positions in Emergent BioSolutions Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,716,599 | $39.5M | 0.00% | +375,137+8.6% | Added |
| Dimensional Fund Advisors LP | 3,076,646 | $25.8M | 0.00% | +319,488+11.6% | Added |
| State Street Corp | 2,929,238 | $24.6M | 0.00% | +79,537+2.8% | Added |
| American Century Companies Inc | 2,770,448 | $23.2M | 0.01% | +344,726+14.2% | Added |
| Vanguard Capital Management LLC | 2,198,839 | $18.4M | 0.00% | −59,156−2.6% | Reduced |
| LSV Asset Management | 1,695,851 | $14.2M | 0.03% | +799,151+89.1% | Added |
| Acadian Asset Management LLC | 1,344,323 | $11.3M | 0.01% | −37,301−2.7% | Reduced |
| Geode Capital Management, LLC | 1,337,243 | $11.2M | 0.00% | +64,334+5.1% | Added |
| Charles Schwab Investment Management Inc | 1,200,791 | $10.1M | 0.00% | −305,284−20.3% | Reduced |
| Oak Hill Advisors LP | 1,113,338 | $9.33M | 1.33% | 00.0% | Unchanged |
Holders of 5% or more of EBS
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Emergent BioSolutions Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 9.00%4.65M shares | +1.70 ppfrom 7.30% | Jul 17, 20252 filings | Jul 28, 2026 | SEC |
| American Century Investment Management Inc | 13G | 5.40%2.77M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Dimensional Fund Advisors LP | 13G | 5.30%2.76M shares | New | Apr 9, 20261 filing | Apr 9, 2026 | SEC |
| State Street Corp | 13G | 5.10%2.70M shares | – | Feb 10, 20225 filings | Feb 9, 2026 | SEC |
Politician trades
All politician trades in EBS3 members of Congress reported 12 trades in Emergent BioSolutions Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 10, 2025 |  Steve Cohen House · TN | Sell | $1K-$15K |
| Dec 13, 2021 |  Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Nov 15, 2021 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Oct 13, 2021 | Josh Gottheimer House · NJ | Sell (partial) | $1K-$15K |
| Mar 10, 2021 | Josh Gottheimer House · NJ | Sell (partial) | $1K-$15K |
House · TN · Jan 10, 2025
Sell$1K-$15K
House · NJ · Dec 13, 2021
Sell$1K-$15K
House · NJ · Nov 15, 2021
Buy$1K-$15K
House · NJ · Oct 13, 2021
Sell (partial)$1K-$15K
House · NJ · Mar 10, 2021
Sell (partial)$1K-$15K